Scleromyxedema in an adult following Sinopharm BBIBP-CorV vaccination: An extremely rare phenomenon.

IF 1.4 Q3 RHEUMATOLOGY

Journal of Scleroderma and Related Disorders Pub Date : 2023-06-01 Epub Date: 2022-06-30 DOI:10.1177/23971983221107321

Amirhossein Parsaei, Somayeh Sadat Rezaei, Alireza Rahmani, Maryam Masoumi, Hojat Dehghanbanadaki, Somayyeh Norouzi, Mohammad Mehdi Riyahi, Reihane Tabaraii, Seyed Mohammad Hashem Montazeri

{"title":"Scleromyxedema in an adult following Sinopharm BBIBP-CorV vaccination: An extremely rare phenomenon.","authors":"Amirhossein Parsaei, Somayeh Sadat Rezaei, Alireza Rahmani, Maryam Masoumi, Hojat Dehghanbanadaki, Somayyeh Norouzi, Mohammad Mehdi Riyahi, Reihane Tabaraii, Seyed Mohammad Hashem Montazeri","doi":"10.1177/23971983221107321","DOIUrl":null,"url":null,"abstract":"Introduction: The Sinopharm BBIBP-CorV vaccine produces a variety of cutaneous adverse effects. Scleromyxedema is a mucinous connective tissue disorder that causes skin thickness and sclerodermoid changes. According to our findings, this is the first case of scleromyxedema induced by the Sinopharm immunization.Case description: We discuss the case of a 75-year-old woman who acquired progressive thickening of the skin in her limbs and trunk after getting the Sinopharm vaccination. Examination, laboratory testing, and a biopsy were used to verify scleromyxedema diagnosis. Intravenous immunoglobulins, mycophenolate mofetil, and prednisolone were used in the treatment of the patient. The outcomes from the 4-month follow-up were reassuring.Conclusion: This study emphasizes the need of considering scleromyxedema as a connective tissue pathology in patients who have recently received Sinopharm vaccine and have similar cutaneous signs.","PeriodicalId":17036,"journal":{"name":"Journal of Scleroderma and Related Disorders","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242695/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Scleroderma and Related Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23971983221107321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The Sinopharm BBIBP-CorV vaccine produces a variety of cutaneous adverse effects. Scleromyxedema is a mucinous connective tissue disorder that causes skin thickness and sclerodermoid changes. According to our findings, this is the first case of scleromyxedema induced by the Sinopharm immunization.

Case description: We discuss the case of a 75-year-old woman who acquired progressive thickening of the skin in her limbs and trunk after getting the Sinopharm vaccination. Examination, laboratory testing, and a biopsy were used to verify scleromyxedema diagnosis. Intravenous immunoglobulins, mycophenolate mofetil, and prednisolone were used in the treatment of the patient. The outcomes from the 4-month follow-up were reassuring.

Conclusion: This study emphasizes the need of considering scleromyxedema as a connective tissue pathology in patients who have recently received Sinopharm vaccine and have similar cutaneous signs.

查看原文本刊更多论文

一名成人接种国药集团 BBIBP-CorV 疫苗后出现硬化性水肿：一种极为罕见的现象

简介国药集团 BBIBP-CorV 疫苗会产生多种皮肤不良反应。硬肿症是一种粘液结缔组织疾病，会导致皮肤增厚和硬皮样改变。根据我们的研究结果，这是首例由国药集团免疫接种诱发的硬皮水肿病例：我们讨论的病例是一名 75 岁的妇女在接种国药控股疫苗后出现四肢和躯干皮肤进行性增厚。通过检查、实验室检测和活组织切片验证了硬肌水肿的诊断。患者接受了静脉注射免疫球蛋白、霉酚酸酯和泼尼松龙治疗。4 个月的随访结果令人欣慰：本研究强调，对于近期接种过国药准字疫苗并有类似皮肤症状的患者，有必要将硬膜水肿视为结缔组织病变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Scleroderma and Related Disorders RHEUMATOLOGY-

CiteScore

4.10

自引率

0.00%

发文量